4-[(5-methyl-7-pyridin-4-yl-6H-thieno[2,3-d]pyridazin-3-yl)methyl]morpholine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-[(5-methyl-7-pyridin-4-yl-6H-thieno[2,3-d]pyridazin-3-yl)methyl]morpholine
• 化学式: C₁₇H₂₀N₄OS
• 分子量: 328.4
• InChiKey: HELLLQWWKUKFBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  65.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS DE LA PHOSPHODIESTÉRASE DE TYPE 10A
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140086A1

  公开（公告）日：2014-09-18

  The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: (I). In formula I the variables X1 is CH or N, X2 is O or S and where R1, R2, R3, R4 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式I的化合物，其N-氧化物、互变体、前药和其药用可接受的盐：（I）。在公式I中，变量X1为CH或N，X2为O或S，其中R1、R2、R3、R4和Q如权利要求中所定义。公式I的化合物，其N-氧化物、互变体、前药和其药用可接受的盐是磷酸二酯酶10A的抑制剂。因此，该发明还涉及利用公式I的化合物、N-氧化物、互变体、前药和其药用可接受的盐制造药物，并且适用于治疗或控制选择自神经学障碍和精神障碍的医学疾病，改善与这些障碍相关的症状，并降低这些障碍的风险。
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：EP2970328A1

  公开（公告）日：2016-01-20